Summary
The bladder cancer
market has remained largely unchanged in the past 10-20 years. However,
significant expansion is expected starting in 2016, with the introduction of
several new therapies that are projected to fuel market growth. In addition,
bladder cancer has a robust early-stage pipeline that will contribute to market
growth beyond the forecast period of 2012-2017.
Get Sample Report @ https://www.wiseguyreports.com/reports/375902-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2017
Currently, the bladder
cancer market is dominated by generic chemotherapy and immunotherapy. Though
initially effective, toxicity and lack of clinical efficacy in improving
overall survival have left the door open for more tolerable and effective drugs
to be developed. In the past, bladder cancer has not been an area of focus for
pharmaceutical companies, but that is rapidly changing as more companies focus
on the bladder cancer market, recognizing the high level of unmet need and
relatively clear regulatory path. During the forecast period, the market
landscape will begin to change dramatically with the introduction of targeted
immunotherapies. These drugs will provide much-needed alternatives to bladder
cancer patients who have not benefitted from traditional treatments.
Highlights
The bladder cancer market is poised to undergo rapid
expansion during the forecast period and beyond. What are the main drivers of
this expansion? What are the main barriers that could dampen this expansion? -
The bladder cancer market is plagued by the presence of high unmet needs not
addressed by current treatments. What are the main unmet needs in this market?
Will the drugs under development fulfil the unmet needs of the bladder cancer
market? - The current bladder cancer market is highly generic. How will the
introduction of targeted immunotherapies, including the much-anticipated
PD-1/PD-L1 class of immune checkpoint inhibitors, change the market landscape?
Key
Findings
The main driver of the rapid expansion of the bladder market
will be the launch of several highly anticipated drugs into the market starting
in 2016. - The second largest driver will be the forecast increase in number of
incident cases in bladder cancer. - To gain approval, it is essential for companies
to demonstrate efficacy in delaying recurrence, but not necessarily improvement
in overall survival. Thus, the bar for approval in bladder cancer is low. - In
the future, companies will have to differentiate their drugs from others in the
same class in order to successfully compete for patient share. - The number of
pipeline agents being developed by small to mid-sized companies represents an
opportunity for large pharma to enter this highly lucrative market through
licensing and marketing partnerships.
Scope
Overview of bladder cancer, including epidemiology,
etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. -
Annualized bladder cancer therapeutics market revenue, annual cost of therapy
and treatment usage pattern data from 2012 and forecast for 5 years to 2017.
Key topics covered include strategic competitor assessment,
market characterization, unmet needs, clinical trial mapping and implications
for the bladder cancer therapeutics market. - Pipeline analysis: comprehensive data
split across different phases, emerging novel trends under development, and
detailed analysis of late-stage pipeline drugs. - Analysis of the current and
future market competition in the global bladder cancer therapeutics market.
Insightful review of the key industry drivers, restraints and challenges. Each
trend is independently researched to provide qualitative analysis of its
implications
The report will enable you to
Develop and design your in-licensing and out-licensing
strategies through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally a list of
acquisition targets included in the pipeline product company list. - Develop
business strategies by understanding the trends shaping and driving the global
bladder cancer therapeutics market. - Drive revenues by understanding the key
trends, innovative products and technologies, market segments, and companies
likely to impact the global bladder cancer therapeutics market in future. -
Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analysing the performance of various competitors. Identify
emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage. - Track drug sales in the
global bladder cancer therapeutics market from 2012-2017. Organize your sales
and marketing efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and strategic
partnerships.
Table of
Contents
11 1.1 List of Tables
16 1.2 List of Figures 20
2 Introduction 21
2.1 Catalyst 21 2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Etiology and Pathophysiology 22
3.1.1 Etiology 22
3.1.2 Pathophysiology 23
3.1.3 Clinical Staging 24
3.2 Prognosis 27
3.3 Quality of Life 28
3.4 Symptoms 29
3.5 Diagnosis 29
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Co-morbidities 31
4.2.1 Smoking is the most significant risk factor for
bladder cancer 32
4.2.2 Up to 25% of male bladder cancer cases are due to
occupational exposure to aromatic amines 33 4.3 Global and Historical Trends 33
4.3.1 Incidence, Mortality, and Five-Year Prevalence 34
4.3.2 Relative Survival 36
4.3.3 Disability-Adjusted Life Years and Years of Life Lost
37
Access Report @ https://www.wiseguyreports.com/sample-request/375902-opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2017
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment